Analyzing proteins in single cancer cells to understand disease better
Official title: Massive single cell proteomics for cancer biology
Funded at Battelle Pacific Northwest Laboratories · NIH-10914966 · Data updated 2026-11-12
This study is looking at a new way to examine proteins in individual cancer cells from patients with multiple myeloma to find unique markers that could help tailor treatments just for you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Battelle Pacific Northwest Laboratories NIH-funded |
| Lab location | 1 site (Richland, United States) |
| Project start | September 20, 2022 |
| Project end | August 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $627,686 |
| NIH project number | 5R01CA272377-03 |
| Project ID | NIH-10914966 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with multiple myeloma who are undergoing treatment.
✕Less likely to help
Patients with cancers other than multiple myeloma or those not undergoing treatment may not benefit from this research.
What this research studies
This research focuses on developing a new technology to analyze proteins in individual cancer cells, particularly in patients with multiple myeloma. By using advanced mass spectrometry techniques, the study aims to uncover the differences in protein expression that may influence how cancer progresses and responds to treatment. Patients' cells will be examined to identify unique protein markers that could inform personalized treatment strategies. The goal is to create a high-throughput platform that can analyze thousands of cells efficiently, providing valuable insights into cancer biology.
Why it matters
Potential benefit: If successful, this research could lead to more effective and personalized treatments for cancer patients by identifying specific protein markers associated with disease progression.
How similar studies have gone: Previous research using single-cell proteomics has shown promise in understanding cancer biology, indicating that this approach could yield significant insights.
Where this research is happening
-
Battelle Pacific Northwest Laboratories
Richland, United States Active
Researchers
- Principal investigator: Pasa-Tolic, Ljiljana — Battelle Pacific Northwest Laboratories
- Study coordinator: Pasa-Tolic, Ljiljana
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.